

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the November 1, 2018 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.html

Please refer to the November 1, 2018 Updates for complete listings of products available by special authorization, restricted benefits, added products, new established interchangeable groupings, products with a price change and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at www.ab.bluecross.ca/dbl/idbl_main1.html is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Auro Pharma Inc. that the shortage for Auro-Ziprasidone 20 mg Capsule (DIN 02449544) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 19, 2018**.

ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE

20 MG CAPSULE

00002449544	AURO-ZIPRASIDONE	AUR	\$ 1.3784
00002298597	ZELDOX	PFI	\$ 1.8197

Alberta Blue Cross has been advised by Auro Pharma Inc. that the shortage for Auro-Ziprasidone 40 mg Capsule (DIN 02449552) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 19, 2018**.

ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE

40 MG CAPSULE

00002449552	AURO-ZIPRASIDONE	AUR	\$ 1.5786
00002298600	ZELDOX	PFI	\$ 2.0845

... continued from previous page

Alberta Blue Cross has been advised by Auro Pharma Inc. that the shortage for Auro-Ziprasidone 60 mg Capsule (DIN 02449560) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 21, 2018**.

ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE

60 MG CAPSULE

00002449560	AURO-ZIPRASIDONE	AUR	\$ 1.5786
00002298619	ZELDOX	PFI	\$ 2.0845

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage for Ketorolac 0.5% Ophthalmic Solution (DIN 02245821) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 26, 2018**.

KETOROLAC TROMETHAMINE

0.5 % OPHTHALMIC SOLUTION

00002245821	KETOROLAC	AAP	\$ 2.6723
00001968300	ACULAR	ALL	\$ 3.5635

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.767 2018/10

